On page 3, please replace the paragraph spanning lines 28-29 with the following paragraph:

Figure 1 depicts the PCR primers used to isolate the cdn-1 probes (SEQ ID NO:1 through SEQ ID NO:5, from top to bottom).

On page 3, please replace the paragraph spanning lines 32-33 with the following paragraph:

Figure 3 depicts the nucleotide sequence (SEQ ID NO:6) and the predicted amino acid sequence (SEQ ID NO:7) of cdn-1.

On page 4, please replace the paragraph spanning lines 4-6 with the following paragraph:

Figure 5 shows the sequence of the cdn-2 cDNA and flanking sequences (SEQ ID NO:8) and the corresponding predicted amino acid sequence (SEQ ID NO:9) of the cdn-2 protein.--

On page 4, please replace the paragraph spanning lines 7-9 with the following paragraph:

Figure 6 shows a comparison of N-terminal amino acid sequences of cdn-1 (SEQ ID NO:10), cdn-2 (SEQ ID NO:11) and known bcl-2 family members (SEQ ID NO:12 through SEQ ID NO:19, from bcl-2 through ced-9).

On page 4, please replace the paragraph spanning lines 10-11 with the following paragraph:

Figure 7 shows the nucleotide sequence (SEQ ID NO:20) and the predicted amino acid sequence (SEQ ID NO:21) of cdn-3.

On page 4, please replace the paragraph spanning lines 20-23 with the following paragraph:

Figure 11 depicts the cdn-1 derivative proteins Δ1, Δ2 and Δ3 (SEQ ID NO:22). The N-terminal residues are indicated by the arrows. The remainder of the derivative proteins is the same as full-length cdn-1.

Please replace the paragraph spanning page 7, line 35 through page 8, line 4, with the following paragraph:

The invention further embodies a variety of DNA vectors having cloned therein the cdn nucleotide sequences encoding CDN proteins. Suitable vectors include any known in the art including, but not limited to, those for use in bacterial, mammalian, yeast and insect expression systems. Specific vectors are known in the art and need not be described in detail herein.

On page 12, please insert the following new paragraph on line 10 prior to the paragraph currently spanning lines 10-20:

--The invention thus encompasses a method of detecting the presence of a CDN protein in a biological sample comprising the steps of: obtaining a cell sample; lysing or permeabilizing the cells to the antibodies; adding anti-CDN-specific antibodies to the cell sample; maintaining the cell sample under conditions that allow the antibodies to complex with the CDN; and detecting the antibody-CDN complexes formed. The cell sample can be comprised of T cells.--

B9

On page 15, please replace the paragraph spanning lines 6-19 with the following paragraph:

The invention also encompasses therapeutic methods and compositions involving treatment of patients with biological modifiers to increase or decrease expression of CDNs. Effective concentrations and dosage regimens may be empirically derived. Such derivations are within the skill of those in the art and depend on, for instance, age, weight and gender of the patient and severity of the disease. Alternatively, patients may be directly treated with either native or recombinant CDNs. The CDNs should be substantially pure and free of pyrogens. It is preferred that the recombinant CDNs be produced in a mammalian cell line so as to ensure proper glycosylation. CDNs may also be produced in an insect cell line and will be glycosylated.

B10

On page 21, please replace the paragraph spanning lines 17-23 with the following paragraph:

--The coding region of cdns can also be ligated into expression vectors capable of stably integrating into other cell types including, but not limited to, cardiomyocytes, neural cell lines such as GTI-7, and TNF cell line HT29, so as to provide a variety of assay systems to monitor the regulation of apoptosis by cdn-1.--

B11

IN THE CLAIMS:

Please amend Claims 32-38 as follows, without prejudice or disclaimer of the subject matter therein.

32. (Once Amended) A composition comprising a monoclonal or polyclonal antibody which specifically binds to a CDN protein selected from the group consisting of: CDN-1 comprising the amino acid sequence of SEQ ID NO:7, CDN-2 comprising the amino acid sequence of SEQ ID NO:9, CDN-3 comprising the amino acid sequence of SEQ ID NO:21 and CDN-1Δ1 comprising the amino acid sequence of SEQ ID NO:22.

B12 Sub C2